{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T17:05:40Z","timestamp":1792256740899,"version":"4.4.0"},"reference-count":67,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T00:00:00Z","timestamp":1715904000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["RC2023"],"award-info":[{"award-number":["RC2023"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100024370","name":"Governo Italiano Ministero dell'Istruzione dell'Universita e della Ricerca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100024370","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Italian Association for Cancer Research","doi-asserted-by":"publisher","award":["IG 2022 \\u2013 ID27728"],"award-info":[{"award-number":["IG 2022 \\u2013 ID27728"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["2022EXSWZ2"],"award-info":[{"award-number":["2022EXSWZ2"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.biopha.2024.116766","type":"journal-article","created":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T20:00:26Z","timestamp":1716494426000},"page":"116766","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Pharmacological inhibition of PDGF-C\/neuropilin-1 interaction: A novel strategy to reduce melanoma metastatic potential"],"prefix":"10.1016","volume":"176","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5958-7497","authenticated-orcid":false,"given":"Claudia","family":"Ceci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Ruffini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3990-4758","authenticated-orcid":false,"given":"Mattia","family":"Falconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Grazia","family":"Atzori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Falzon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7340-5613","authenticated-orcid":false,"given":"Flavia","family":"Lozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Iacovelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"D\u2019Atri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0221-768X","authenticated-orcid":false,"given":"Grazia","family":"Graziani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro Miguel","family":"Lacal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2024.116766_bib1","first-page":"1","article-title":"Melanoma","volume":"1","author":"Schadendorf","year":"2015","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.biopha.2024.116766_bib2","doi-asserted-by":"crossref","first-page":"9506","DOI":"10.1200\/JCO.2021.39.15_suppl.9506","article-title":"CheckMate 067: 6.5-year outcomes in patients (pts) with advanced melanoma","volume":"39","author":"Wolchok","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2024.116766_bib3","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1200\/JCO.21.02229","article-title":"Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma","volume":"40","author":"Wolchok","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2024.116766_bib4","doi-asserted-by":"crossref","first-page":"333","DOI":"10.4149\/301_151015N533","article-title":"Current trends in the treatment of malignant melanoma","volume":"63","author":"Valko-Rokytovska","year":"2016","journal-title":"Neoplasma"},{"key":"10.1016\/j.biopha.2024.116766_bib5","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.lfs.2017.02.011","article-title":"Towards therapeutic advances in melanoma management: an overview","volume":"17","author":"Singh","year":"2017","journal-title":"Life Sci."},{"key":"10.1016\/j.biopha.2024.116766_bib6","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2147\/ITT.S134842","article-title":"Melanoma treatment in review","volume":"7","author":"Domingues","year":"2018","journal-title":"ImmunoTargets Ther."},{"key":"10.1016\/j.biopha.2024.116766_bib7","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1056\/NEJMoa1904059","article-title":"Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma","volume":"381","author":"Robert","year":"2019","journal-title":"N. Engl. Med."},{"key":"10.1016\/j.biopha.2024.116766_bib8","doi-asserted-by":"crossref","first-page":"5225","DOI":"10.1158\/1078-0432.CCR-21-0809","article-title":"5-Year Outcomes with cobimetinib plus vemurafenib in BRAFV600 mutation-positive advanced melanoma: extended follow-up of The coBRIM study","volume":"27","author":"Ascierto","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2024.116766_bib9","doi-asserted-by":"crossref","first-page":"4178","DOI":"10.1200\/JCO.21.02659","article-title":"COLUMBUS 5-year update: a randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma","volume":"40","author":"Dummer","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2024.116766_bib10","doi-asserted-by":"crossref","first-page":"66833","DOI":"10.18632\/oncotarget.18706","article-title":"Platelet-derived growth factor-C promotes human melanoma aggressiveness through activation of neuropilin-1","volume":"8","author":"Ruffini","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.biopha.2024.116766_bib11","doi-asserted-by":"crossref","first-page":"E545","DOI":"10.1002\/ijc.29252","article-title":"Cilengitide downmodulates invasiveness and vasculogenic mimicry of neuropilin 1 expressing melanoma cells through the inhibition of \u03b1v\u03b25 integrin","volume":"136","author":"Ruffini","year":"2015","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.biopha.2024.116766_bib12","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.mam.2017.09.005","article-title":"Platelet-derived growth factor-C and -D in the cardiovascular system and diseases","volume":"62","author":"Lee","year":"2018","journal-title":"Mol. Asp. Med."},{"key":"10.1016\/j.biopha.2024.116766_bib13","doi-asserted-by":"crossref","first-page":"309","DOI":"10.18632\/oncotarget.141","article-title":"VEGF-independent angiogenic pathways induced by PDGF-C","volume":"1","author":"Li","year":"2010","journal-title":"Oncotarget"},{"key":"10.1016\/j.biopha.2024.116766_bib14","doi-asserted-by":"crossref","first-page":"27406","DOI":"10.1074\/jbc.M101056200","article-title":"Platelet-derived growth factor C (PDGF-C), a novel growth factor that binds to PDGF alpha and beta receptor","volume":"276","author":"Gilbertson","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2024.116766_bib15","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0925-4773(00)00425-1","article-title":"The mouse Pdgfc gene: dynamic expression in embryonic tissues during organogenesis","volume":"96","author":"Ding","year":"2000","journal-title":"Mech. Dev."},{"key":"10.1016\/j.biopha.2024.116766_bib16","doi-asserted-by":"crossref","first-page":"309","DOI":"10.18632\/oncotarget.141","article-title":"VEGF-independent angiogenic pathways induced by PDGF-C","volume":"1","author":"Li","year":"2010","journal-title":"Oncotarget"},{"key":"10.1016\/j.biopha.2024.116766_bib17","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3892\/ijo.2013.1948","article-title":"Neuropilin-1 expression promotes invasiveness of melanoma cells through vascular endothelial growth factor receptor-2-dependent and -independent mechanisms","volume":"43","author":"Ruffini","year":"2013","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.biopha.2024.116766_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fonc.2015.00125","article-title":"Neuropilin-1 as therapeutic target for malignant melanoma","volume":"5","author":"Graziani","year":"2015","journal-title":"Front Oncol."},{"key":"10.1016\/j.biopha.2024.116766_bib19","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1200\/JCO.2012.46.2762","article-title":"Markers of response for the antiangiogenic agent bevacizumab","volume":"31","author":"Lambrechts","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2024.116766_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.phrs.2023.106782","article-title":"Targeting of PDGF-C\/NRP-1 autocrine loop as a new strategy for counteracting the invasiveness of melanoma resistant to BRAF inhibitors","volume":"192","author":"Ruffini","year":"2023","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.biopha.2024.116766_bib21","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1158\/0008-5472.CAN-10-2602","article-title":"Glioblastoma recurrence after cediranib therapy in patients: lack of \u201crebound\u201d revascularization as mode of escape","volume":"71","author":"di Tomaso","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.biopha.2024.116766_bib22","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1111\/neup.12111","article-title":"Angiogenesis and expression of PDGF-C, VEGF, CD105 and HIF-1\u03b1 in human glioblastoma","volume":"34","author":"Clara","year":"2014","journal-title":"Neuropathology"},{"key":"10.1016\/j.biopha.2024.116766_bib23","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ccr.2008.12.004","article-title":"PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment","volume":"15","author":"Crawford","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1016\/j.biopha.2024.116766_bib24","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.semcancer.2018.01.014","article-title":"Genetic status of KRAS influences Transforming Growth Factor beta (TGF-\u03b2) signaling: an insight into Neuropilin-1 (NRP1) mediated tumorigenesis","volume":"54","author":"Vivekanandhan","year":"2019","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.biopha.2024.116766_bib25","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s10637-014-0071-z","article-title":"A phase I study of the human monoclonal anti-NRP1 antibody MNRP1685A in patients with advanced solid tumors","volume":"32","author":"Weekes","year":"2014","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.biopha.2024.116766_bib26","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1007\/s00280-014-2426-8","article-title":"A Phase Ib study evaluating MNRP1685A, a fully human anti-NRP1 monoclonal antibody, in combination with bevacizumab and paclitaxel in patients with advanced solid tumors","volume":"73","author":"Patnaik","year":"2014","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.biopha.2024.116766_bib27","doi-asserted-by":"crossref","first-page":"29120","DOI":"10.1074\/jbc.R115.687327","article-title":"Neuropilin functions as an essential cell surface receptor","volume":"290","author":"Guo","year":"2015","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2024.116766_bib28","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.apsb.2021.09.006","article-title":"Repurposing non-oncology small-molecule drugs to improve cancer therapy: Current situation and future directions","volume":"12","author":"Fu","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.biopha.2024.116766_bib29","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1002\/jcc.21256","article-title":"AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility","volume":"30","author":"Morris","year":"2009","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.biopha.2024.116766_bib30","doi-asserted-by":"crossref","first-page":"11082","DOI":"10.1074\/jbc.M111.331140","article-title":"Structural basis for selective vascular endothelial growth factor-A (VEGF-A) binding to neuropilin-1","volume":"287","author":"Parker","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2024.116766_bib31","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jcc.21334","article-title":"AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading","volume":"31","author":"Trott","year":"2010","journal-title":"J. Comput. Chem."},{"issue":"Suppl 1","key":"10.1016\/j.biopha.2024.116766_bib32","article-title":"PoseView -- molecular interaction patterns at a glance","volume":"2","author":"Stierand","year":"2010","journal-title":"J. Cheminform."},{"key":"10.1016\/j.biopha.2024.116766_bib33","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1111\/j.1365-2133.2010.10200.x","article-title":"Expression of the soluble vascular endothelial growth factor receptor-1 in cutaneous melanoma: role in tumour progression","volume":"164","author":"Ruffini","year":"2011","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.biopha.2024.116766_bib34","doi-asserted-by":"crossref","first-page":"17114","DOI":"10.1074\/jbc.M301728200","article-title":"Platelet-derived growth factor (PDGF)-C, a PDGF family member with a vascular endothelial growth factor-like structure","volume":"278","author":"Reigstad","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2024.116766_bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1758-2946-3-33","article-title":"Open Babel: An open chemical toolbox","volume":"3","author":"O'Boyle","year":"2011","journal-title":"J. Cheminform."},{"key":"10.1016\/j.biopha.2024.116766_bib36","doi-asserted-by":"crossref","first-page":"6152","DOI":"10.1073\/pnas.0700043104","article-title":"Structural basis for ligand and heparin binding to neuropilin B domains","volume":"104","author":"Vander Kooi","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.biopha.2024.116766_bib37","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1002\/jcc.20084","article-title":"UCSF Chimera--a visualization system for exploratory research and analysis.","volume":"25","author":"Pettersen","year":"2004","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.biopha.2024.116766_bib38","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1046\/j.1365-2125.1999.00979.x","article-title":"Plasma concentrations of disodium cromoglycate after various inhalation methods in healthy subjects","volume":"48","author":"Kato","year":"1999","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.biopha.2024.116766_bib39","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.jpba.2009.11.015","article-title":"Quantitative determination of pimozide in human plasma by liquid chromatography-mass spectrometry and its application in a bioequivalence study","volume":"51","author":"Yan","year":"2010","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.biopha.2024.116766_bib40","first-page":"1","article-title":"Improved bioavailability of cromolyn sodium using inhaled PA101 delivered via eFlow\u00ae nebulizer","volume":"7","author":"Abd-Elaziz","year":"2020","journal-title":"Eur. Clin. Respir. J."},{"key":"10.1016\/j.biopha.2024.116766_bib41","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0168-8227(86)80007-9","article-title":"Serum gliclazide concentration in diabetic patients. Relationship between gliclazide dose and serum concentration","volume":"2","author":"Shiba","year":"1986","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.biopha.2024.116766_bib42","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s10637-020-01047-5","article-title":"Characterization of the pharmacokinetics of entrectinib and its active M5 metabolite in healthy volunteers and patients with solid tumors","volume":"39","author":"Meneses-Lorente","year":"2021","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.biopha.2024.116766_bib43","doi-asserted-by":"crossref","first-page":"120","DOI":"10.59566\/IJBS.2010.6120","article-title":"Determination of azelastine in human plasma by validated liquid chromatography coupled to tandom mass spectrometry (LC-ESI\/MS\/MS) for the clinical studies","volume":"6","author":"Park","year":"2010","journal-title":"Int. J. Biomed. Sci."},{"key":"10.1016\/j.biopha.2024.116766_bib44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7554\/eLife.90234","article-title":"Cas phosphorylation regulates focal adhesion assembly","volume":"12","author":"Kumar","year":"2023","journal-title":"Elife"},{"key":"10.1016\/j.biopha.2024.116766_bib45","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.cellsig.2012.12.019","article-title":"p130Cas: a key signalling node in health and disease","volume":"25","author":"Barrett","year":"2013","journal-title":"Cell Signal"},{"key":"10.1016\/j.biopha.2024.116766_bib46","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1042\/BJ20100580","article-title":"Neuropilin-1 mediates PDGF stimulation of vascular smooth muscle cell migration and signalling via p130Cas","volume":"435","author":"Pellet-Many","year":"2011","journal-title":"Biochem. J."},{"key":"10.1016\/j.biopha.2024.116766_bib47","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1128\/MCB.00903-10","article-title":"Neuropilin-1 signaling through p130Cas tyrosine phosphorylation is essential for growth factor-dependent migration of glioma and endothelial cells","volume":"31","author":"Evans","year":"2011","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.biopha.2024.116766_bib48","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.phrs.2016.07.017","article-title":"Vemurafenib resistance increases melanoma invasiveness and modulates the tumor microenvironment by MMP-2 upregulation","volume":"111","author":"Sandri","year":"2016","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.biopha.2024.116766_bib49","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.3892\/ijo.2016.3594","article-title":"Targeting the PI3K\/AKT\/mTOR pathway overcomes the stimulating effect of dabrafenib on the invasive behavior of melanoma cells with acquired resistance to the BRAF inhibitor","volume":"49","author":"Caporali","year":"2016","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.biopha.2024.116766_bib50","doi-asserted-by":"crossref","first-page":"2887","DOI":"10.3892\/or.2013.2791","article-title":"Platelet-derived growth factor C and calpain-3 are modulators of human melanoma cell invasiveness","volume":"30","author":"Ruffini","year":"2013","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.biopha.2024.116766_bib51","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/joim.12690","article-title":"Involvement of platelet-derived growth factor ligands and receptors in tumorigenesis","volume":"283","author":"Heldin","year":"2018","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.biopha.2024.116766_bib52","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.3892\/mmr.2015.3752","article-title":"Increased expression of neuropilin 1 in melanoma progression and its prognostic significance in patients with melanoma","volume":"12","author":"Lu","year":"2015","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.biopha.2024.116766_bib53","first-page":"1","article-title":"Development of monoclonal anti-PDGF-CC antibodies as tools for investigating human tissue expression and for blocking PDGF-CC induced PDGFR\u03b1 signalling in vivo","volume":"13","author":"Li","year":"2018","journal-title":"PloS One"},{"key":"10.1016\/j.biopha.2024.116766_bib54","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/bs.podrm.2017.02.003","article-title":"Gliclazide","volume":"42","author":"Al-Omary","year":"2017","journal-title":"Profiles Drug Subst. Excip. Relat. Methodol."},{"key":"10.1016\/j.biopha.2024.116766_bib55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejphar.2019.172598","article-title":"Sulfonylurea derivatives and cancer, friend or foe?","volume":"861","author":"Hendriks","year":"2019","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.biopha.2024.116766_bib56","doi-asserted-by":"crossref","first-page":"5253","DOI":"10.1007\/s11033-011-1323-z","article-title":"Gliclazide may have an antiapoptotic effect related to its antioxidant properties in human normal and cancer cells, J","volume":"39","author":"Sliwinska","year":"2012","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.biopha.2024.116766_bib57","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fonc.2021.665276","article-title":"Identification of prognostic signature and gliclazide as candidate drugs in lung adenocarcinoma","volume":"11","author":"Cheng","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.biopha.2024.116766_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104609","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors: a 2020 update","volume":"152","author":"Roskoski","year":"2020","journal-title":"Pharm. Res."},{"key":"10.1016\/j.biopha.2024.116766_bib59","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","article-title":"trial investigators, Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials","volume":"21","author":"Doebele","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.biopha.2024.116766_bib60","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1158\/1078-0432.CCR-21-3597","article-title":"Updated integrated analysis of the efficacy and safety of entrectinib in patients with NTRK fusion-positive solid tumors","volume":"28","author":"Demetri","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2024.116766_bib61","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S1470-2045(19)30690-4","article-title":"trial investigators, Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials","volume":"21","author":"Drilon","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.biopha.2024.116766_bib62","first-page":"1","article-title":"Long-term efficacy and safety of entrectinib in ROS1 fusion-positive NSCLC","volume":"3","author":"Drilon","year":"2022","journal-title":"JTO Clin. Res. Rep."},{"issue":"1","key":"10.1016\/j.biopha.2024.116766_bib63","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/ncomms5846","article-title":"The landscape of kinase fusions in cancer","volume":"5","author":"Stransky","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2024.116766_bib64","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ncomms4116","article-title":"Kinase fusions are frequent in Spitz tumours and spitzoid melanomas","volume":"5","author":"Wiesner","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2024.116766_bib65","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1158\/1535-7163.MCT-17-0472","article-title":"ALK inhibitor response in melanomas expressing EML4-ALK fusions and alternate ALK isoforms","volume":"17","author":"Couts","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.biopha.2024.116766_bib66","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1159\/000534475","article-title":"Entrectinib for NTRK fusion-positive metastatic melanoma progressing on combined PD-1 and CTLA-4 inhibition: a case report","volume":"16","author":"Dawood","year":"2023","journal-title":"Case Rep. Oncol."},{"issue":"6","key":"10.1016\/j.biopha.2024.116766_bib67","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1093\/neuonc\/noaa052","article-title":"Entrectinib, a TRK\/ROS1 inhibitor with anti-CNS tumor activity: differentiation from other inhibitors in its class due to weak interaction with P-glycoprotein","volume":"22","author":"Fischer","year":"2020","journal-title":"Neuro Oncol."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332224006504?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332224006504?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T23:07:52Z","timestamp":1781651272000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332224006504"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":67,"alternative-id":["S0753332224006504"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2024.116766","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacological inhibition of PDGF-C\/neuropilin-1 interaction: A novel strategy to reduce melanoma metastatic potential","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2024.116766","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"116766"}}